Genotyping of rs12997 SNP in binding site of let-7b miRNA in colorectal cancer
Keywords:
Genotyping, rs12997 SNP, binding site, let-7b miRNA, colorectal cancer.Abstract
The current study aims to Genotyping of rs12997 SNP in binding site of let-7b miRNA in ACVR1 gene using PCR-sequencing, the results found the percentage of deletion mutation in patient was 66.66% while in control group 3.7 % in highly significant differences, other study characteristic non- significantly association with rs12997 belong to the gender the deletion mutation was higher in male 41.66% than female 25%, the percentage of deletion mutation was a same percentage (10.41%) in both in Adenocarcinoma and Mucinous adenocarcinoma, in cancer grade the highest percentage was observed in well differentiated (37.5%) and moderate differentiated (29.16%), the deletion mutation appeared in all grades of lymph node metastases, in the N0 (31.25%), N1 (14.58 %) , N2 (8.33%), N1b (2.08%), N2b (6.25%) and N2a (4.16%). the highest percentage of deletion mutation observed in III and I (20.83%) , and in II ,IIA and IIIb (6.25%), According to metastasis the M1 deletion mutation was (4.16%) whlile in the Mx the deletion mutation was (2.08%) , non-sig assocation abserved between genotypes (CT, CC, and TT) between patients and control (p 1.3333, 0.3811) and also non- significant association with cancer characteristic in current study. The findings concluded that the deletion mutation was strong association with colorectal cancer but genotypes didn't effecte in colorectal cancer characteristics.
Downloads
References
Skeeles LE, Fleming JL, Mahler KL, Toland AE. The impact of
' UTR variants on differential expression of candidate
cancer susceptibility genes. PLoS ONE. 2013;8:e58609.
Iorio MV, Croce CM. MicroRNA dysregulation in cancer:
diagnostics, monitoring and therapeutics. A
comprehensive review. EMBO Mol Med. 2012;4:143-59.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al.
Frequent deletions and down-regulation of micro-RNA genes
miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
Proc Natl Acad Sci USA. 2002;99:15524-9. Cargill M,
Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, et al.
Characterization of single-nucleotide polymorphisms in
coding regions of human genes. Nat Genet. 1999;22:231.
Sukhumsirichart W. Polymorphisms. In Genetic Diversity and
disease susceptibility. IntechOpen. 2018;76:728.Altshuler D, Donnelly P, Consortium IH. A haplotype map of
the human genome. Nature. 2005;437:1299.
Guo L, Du Y, Chang S, Zhang K, Wang J. rSNPBase: a
database for curated regulatory SNPs. Nucleic Acids Res.
O13;42(D1): D1O33-D9.
Steri M, Idda ML, Whalen MB, Orru V. Genetic variants in
mRNA untranslated regions. Wiley Interdiscip Rev: RNA,
;9:e1474.
Schwerk J, Savan R. Translating the untranslated region.
Jlmmunol. 2015;195:2963-71.
Sukhumsirichart W. Polymorphisms. In Genetic Diversity and
disease susceptibility. IntechOpen. 2018;76:728.
Mullany LE, Herrick JS, Wolff RK, Slattery ML. Single
nucleotide polymorphisms within MicroRNAs, MicroRNA
targets, and MicroRNA biogenesis genes and their
impact on colorectal cancer survival. Genes
Chromosomes Cancer. 2017 Apr;56(4):285-295. doi:
1002/gcc.22434. Epub 2017 Jan 25. PMID: 27859935;
PMCID: PMC6007859.
Altshuler D, Donnelly P, Consortium IH. A haplotype map of
the human genome. Nature. 2005;437:1299.
Guo L, Du Y, Chang S, Zhang K, Wang J. rSNPBase: a
database for curated regulatory SNPs. Nucleic Acids Res.
;42(D1):D1033-D9. PubMed PubMed
Central Article CAS Google Scholar
Steri M, Idda ML, Whalen MB, Orru V. Genetic variants in
mRNA untranslated regions. Wiley Interdiscip Rev: RNA.
a;9:e1474.
Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P,
Vodickova L, et al. Polymorphisms within micro-RNAbinding sites and risk of sporadic colorectal cancer.
Carcinogenesis. 2008;29:579-84.
Ding H-X, Lv Z, Yuan Y, Xu Q. MiRNA polymorphisms and
cancer prognosis: a systematic review and meta¬
analysis. Front Oncol. 2018;8:596. PubMed PubMed
Central Article Google Scholar
Ryan BM, Robles Al, Harris CC. Genetic variation in
microRNA networks: the implications for cancer
research. Nat Rev Cancer. 2010;10:389
Renlund N, O'Neill FH, Zhang L, Sidis Y, Teixeira J. Activin
receptor-like kinase-2 inhibits activin signaling by
blocking the bind¬
ing of activin to its type II receptor. J Endocrinol. 2007;
:95-103.
Wu TC, Jih MH, Wang L, Wan YJ. Expression of activin
receptor Hand 1 1B mRNA isoforms in mouse reproductive
organs and oocytes.Mol Reprod Dev. 1994;38:9-15.
Donaldson CJ, Mathews LS, Vale WW. Molecular cloning
andbinding properties of the human type II activin
receptor. BiochemBiophys Res Comm. 1992;184: 310-6.
Eresen Yazicioglu C, Karatosun V, Kizildag S, Ozsoylu D,
KavukcuS. Acvrl Gene mutations in four Turkish patients
diagnosed asfibrodysplasia ossificans progressiva. Gene.
;515:444-6.
Wiley LA, Rajagopal R, Dattilo LK, Beebe DC. The tumor
suppressor gene TRP53 protects the mouse lens against
posterior subcapsularcataracts and the bmp receptor
ACVR1 acts as a tumor suppressor in the lens. Disease
Models Meeh. 2011; 4: 484-95.
Ambrosio EP, Drigo SA, Bergamo NA, Rosa FE, Bertonha FB,
deAbreu FB, et al. Recurrent copy number gains of
ACVR1 andcorresponding transcript overexpression are
associated with survivalin head and neck sguamous cell
carcinomas. Histopathology.
;59:81-9.
Gong, Jing; Shen, Na; Zhang, Hong-Mei; Zhong, Rong; Chen,
Wei; Miao, Xiaoping; Guo, An-Yuan (2014). A genetic
variant in microRNA target site of TGF- signaling
pathway increases the risk of colorectal cancer in a
Chinese population. Tumor Biology, 35(5), 4301-4306.
doi:10.1007/s13277-013-1562-9.
Klein U, Lia M, Crespo M, Siegel R, Shen G, Mo T et al. The
DLEU2/miR-15a/16-1 cluster controls B cell proliferation
and its deletion leads to chronic lymphocytic leukemia.
Cancer Cell 2010;17: 28-40.Return to ref 9 in article
Calin GA, Croce CM . MicroRNAs and chromosomal
abnormalities in cancer cells. Oncogene 2006; 25: 6202-
CAS PubMed Google Scholar
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E,
Yendamuri S et al. Human microRNA genes are
freguently located at fragile sites and genomic regions
involved in cancers. Proc Natl Acad Sci USA 2004; 101:
-3004.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et
al. Freguent deletions and down-regulation of micro¬
RNA genes miR15 and miR16 at 13g14 in chronic
lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99:
-15529.
Tagawa H, Seto M . A microRNA cluster as a target of
genomic amplification in malignant lymphoma.
Leukemia 2005; 19: 2013-2016. CAS PubMed Google
Scholar
Hayashita Y, Osada H, Tatematsu Y, Yamada H,
Yanagisawa K, Tomida S et al. A polycistronic microRNA
cluster, miR-17-92, is overexpressed in human lung
cancers and enhances cell proliferation. Cancer Res
; 65: 9628-9632. CAS PubMed Google Scholar
Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de
Keersmaecker K, McJunkin K et al. Genome-wide RNAmediated interference screen identifies miR-19 targets in
Notch-induced T-cell acute lymphoblastic leukaemia.
Nat Cell Biol 2010; 12: 372-379.CAS PubMed PubMed
Central Google Scholar
Zhang L, Huang J, Yang N, Greshock J, Megraw MS,
Giannakakis A et al. MicroRNAs exhibit high freguency
genomic alterations in human cancer. Proc Natl Acad Sci
USA 2006; 103: 9136-9141. CAS PubMed PubMed
Central Google Scholar
Peng, Y., Croce, C. The role of MicroRNAs in human cancer.
Sig Transduct Target Ther 1, 15004 (2016).
https://doi.Org/10.1038/sigtrans.2015.4
Martello, G.; Rosato, A.; Ferrari, F.; Manfrin, A.; Cordenonsi,
M.; Dupont, S.; Enzo, E.; Guzzardo, V.; Rondina, M.;
Spruce, T.; et al. A MicroRNA targeting dicer for
metastasis control. Cell 2010, 141, 1195-1207. [CrossRef]
lliou, M.S.; da Silva-Diz, V.; Carmona, F.J.; RamalhoCarvalho, J.; Heyn, H.; Villanueva, A.; Munoz, P.; Esteller,
M. Impaired DICER1 function promotes sternness and
metastasis in colon cancer. Oncogene 2014, 33, 4003-
[CrossRef].
Lai, H.H.; Li, J.N.; Wang, M.Y.; Huang, H.Y.; Croce, C.M.; Sun,
H.L.; Lyu, Y.J.; Kang, J.W.; Chiu, C.F.; Hung, M.C.; et al.
HIF-1alpha promotes autophagic proteolysis of Dicer
and enhances tumor metastasis. J. Clin. Investig. 2018,
, 625-643. [CrossRef][PubMed]
van Kouwenhove, M.; Kedde, M.; Agami, R. MicroRNA
regulation by RNA-binding proteins and its implications
for cancer. Nat. Rev. Cancer 2011,11, 644-656. [CrossRef]
Viswanathan, S.R.; Powers, J.T.; Einhorn, W.; Hoshida, Y.; Ng, T.L;
Toffanin, S.; O'Sullivan, M.; Lu, J.; Phillips, L.A.; Lockhart; V.L;et
al. Lin28 promotes transformation and is associated with
advanced human malignancies.Nat.Genet. 2009, 41,843-848.[CrossRef]
Cho, J.; Chang, H.; Kwon, S.C.; Kim, B.; Kim, Y.; Choe, J.; Ha,
M.; Kim, Y.K.; Kim, V.N. LIN28A is a suppressor of ERassociated translation in embryonic stem cells. Cell 2012,
, 765-777. [CrossRef] [PubMed].
Shyh-Chang, N.; Daley, G.Q. Lin28: Primal regulator of
growth and metabolism in stem cells. Cell Stem Cell
, 12, 395-406.
[CrossRef]
Newman, M.A.; Thomson, J.M.; Hammond, S.M. Lin-28
interaction with the Let-7 precursor loop mediates
regulated microRNA
processing. RNA 2008, 14, 1539-1549. [CrossRef]
Piskounova, E.; Polytarchou, C.; Thornton, J.E.; LaPierre,
R.J.; Pothoulakis, C.; Hagan, J.P.; lliopoulos, D.; Gregory,
R.l. Lin28A
and Lin28B inhibit let-7 microRNA biogenesis by distinct
mechanisms. Cell 2011,147, 1066-1079. [CrossRef].
Michlewski, G.; Caceres, J.F. Post-transcriptional control of
miRNA biogenesis. RNA 2019, 25, 1-16. [CrossRef]
[PubMed]
Heo, I.; Joo, C.; Cho, J.; Ha, M.; Han, J.; Kim, V.N. Lin28
mediates the terminal uridylation of let-7 precursor
MicroRNA. Mol. Cell
, 32, 276-284. [CrossRef] [PubMed].
Viswanathan, S.R.; Powers, J.T.; Einhorn, W.; Hoshida, Y.; Ng,
T.L.; Toffanin, S.; O'Sullivan, M.; Lu, J.; Phillips, L.A.;
Lockhart, V.L.; et al. Lin28 promotes transformation and
is associated with advanced human malignancies. Nat.
Genet. 2009, 41,
-848. [CrossRef]
Heo, I.; Joo, C.; Kim, Y.K.; Ha, M.; Yoon, M.J.; Cho, J.; Yeom,
K.H.; Han, J.; Kim, V.N. TUT4 in concert with Lin28
suppresses
microRNA biogenesis through pre-microRNA uridylation.
Cell 2009, 138, 696-708. [CrossRef] [PubMed]
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
